Clin2
NCT06157502Possibly a fitRecruiting

Shuxuening with clot-busting treatment for ischemic stroke

Ischemic Stroke, Acute

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests if adding the herbal injection Shuxuening to standard clot-busting treatment improves recovery for people having an ischemic stroke. It is for adults within 6 hours of symptom onset who are already receiving a clot-dissolving medication.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
1,380 people
Ages
18 years to 100 years
Study type
Interventional

Who can take part

  • You must be 18 years old or older.
  • You must have been diagnosed with an acute ischemic stroke (a stroke from a blocked blood vessel).
  • You must be within 6 hours of your stroke symptoms starting.
  • You must have received or plan to receive a clot-busting medicine (intravenous thrombolysis).
  • Your stroke symptoms should be moderate, not too mild or too severe (NIHSS score between 4 and 25).
  • You should not have significant bleeding or other brain conditions (like tumors or malformations), and you must not be allergic to ginkgo biloba.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07324837Recruiting· Phase 3
Study of a clot-busting drug for stroke up to 24 hours later

This trial tests a single dose of a new clot-dissolving medicine for people who had a stroke 4.5 to 24 hours ago. It may help if you cannot have standard treatments like a clot-removal procedure or other clot-busting drugs.

Ryazan, Ryazan Oblast
NCT07279493Recruiting· Phase 2
Testing KPCXM18 injection for acute ischemic stroke within 12 hours

This trial tests an investigational injection called KPCXM18 for people having an acute ischemic stroke. It is given within 12 hours of symptom onset, in addition to standard clot-dissolving treatment, to see if it improves recovery and safety.

Beijing, Beijing Municipality
NCT07205328Recruiting· Phase 2
Testing MT200605 for acute ischemic stroke

This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.

Beijing, Beijing Municipality
NCT06761183Not yet recruiting· Early Phase 1
NXL-001 for stroke recovery: a safety study

This trial tests a new treatment called NXL-001 for people who have had a stroke affecting movement. The goal is to see if it is safe and if it can help improve motor function. It is for those who still have moderate to severe weakness 2-4 months after their stroke.

Beijing, Beijing Municipality
NCT07520565Recruiting· Phase 3
Emergency stroke treatment with BXOS110 within 3 hours

This trial tests whether BXOS110, an experimental injection, can help people recover better after an acute ischemic stroke (a stroke caused by a blood clot) when given within 3 hours of symptom onset. The study compares BXOS110 to a placebo to see if it reduces disability and improves recovery.

Hengshui, Hebei
NCT07241520Recruiting· Phase 3
Testing SHPL-49 injection for recent stroke patients

This trial tests a new medication, SHPL-49, given as an injection to people who have just had a stroke caused by a blood clot (ischemic stroke). It is for patients who are already receiving standard clot-busting treatment within 8 hours of symptoms starting. The study will see if adding this drug helps improve recovery.

Linfen, Shanxi

Hear when a new Ischemic Stroke, Acute trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.